^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Endometrial Cancer

    Related cancers:
    1d
    WF-1804CD: Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (clinicaltrials.gov)
    P=N/A, N=600, Completed, Wake Forest University Health Sciences | Active, not recruiting --> Completed
    Trial completion
    1d
    Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial. (PubMed, Nat Commun)
    Based on preclinical studies showing synergism with simultaneous inhibition of the estrogen receptor (ER), CDK4/6 and PI3K pathways and based on window of opportunity studies showing that metformin suppresses PI3K/mTOR signaling in endometrial cancer (EC), we conduct a non-randomized phase 2 study of letrozole/abemaciclib/metformin in ER positive endometrioid EC (NCT03675893). There are no objective responses among TP53 mutated ECs and among NSMP (no specific molecular profile) tumors with RB1 or CCNE1 alterations; CTNNB1 mutations correlate with clinical benefit. Pharmacokinetic analyses demonstrate that administration of letrozole and abemaciclib with metformin result in a more than 3-fold increase in metformin exposure.
    P2 data • Journal
    |
    ER (Estrogen receptor) • TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CCNE1 (Cyclin E1) • CDK4 (Cyclin-dependent kinase 4) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    TP53 mutation • ER positive
    |
    Verzenio (abemaciclib) • letrozole • metformin
    1d
    CATALYST: Choices About Genetic Testing And Learning Your Risk With Smart Technology (clinicaltrials.gov)
    P=N/A, N=50, Completed, Rutgers, The State University of New Jersey | Active, not recruiting --> Completed
    Trial completion
    1d
    EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors (clinicaltrials.gov)
    P1/2, N=160, Not yet recruiting, Eikon Therapeutics
    New P1/2 trial • Checkpoint inhibition • Mismatch repair • MSI-H • dMMR
    |
    Keytruda (pembrolizumab)
    2d
    TGFBR2 coordinates the endometrial response to estrogen, regulating endometrial hyperplasia and fertility. (PubMed, Proc Natl Acad Sci U S A)
    By integrating ER and SMAD4 genome-wide binding studies with transcriptomic datasets, we demonstrate that both ER and SMAD4 are required for Pgr transcription. In this study, we highlight the importance of TGFβR2 in endometrial function and female fertility and shed light on the potential involvement of TGFβ signaling in estrogen and progesterone response regulation during early pregnancy.
    Journal
    |
    PGR (Progesterone receptor) • SMAD4 (SMAD family member 4) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • FOXA2 (Forkhead Box A2)
    2d
    Utility of HoxB13 in differential diagnosis of female genital tract lesions with putative prostatic differentiation. (PubMed, Virchows Arch)
    No ABC showed AR positivity, while this was observed in rare cells (IRS 1-2) in 30.8%, 16.6%, and 37.5% of TSCs, EPTs, and ABHs, respectively. HoxB13 can be a useful and reliable marker for identification of TSPs, EPTs and ABCs.
    Journal
    |
    AR (Androgen receptor) • HOXB13 (Homeobox B13) • NKX3-1 (NK3 homeobox 1)
    |
    AR positive
    2d
    Curcumin Analogues Trigger HMOX1-Mediated Ferroptosis to Halt Endometrial Cancer Growth. (PubMed, bioRxiv)
    Cytotoxicity and colony formation were evaluated using CyQUANT assays, with pharmacological inhibitors (ZnPP, Liproxstatin-1, Z-VAD-FMK) and HMOX1 siRNA to dissect the roles of ferroptosis and apoptosis...HO-3867 and AKT-100 induce HMOX1-mediated ferroptosis and apoptosis, effectively suppressing endometrial cancer cell growth. These findings support the therapeutic potential of curcumin analogues and provide a foundation for in vivo studies targeting HMOX1 in endometrial cancer.
    Journal
    |
    HMOX1 (Heme Oxygenase 1)
    |
    liproxstatin-1
    2d
    ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors (clinicaltrials.gov)
    P=N/A, N=384, Recruiting, AstraZeneca | Trial completion date: Nov 2025 --> Apr 2026 | Trial primary completion date: Nov 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    organoids endo: Generation of Endometrial Carcinoma Organoids (clinicaltrials.gov)
    P=N/A, N=20, Recruiting, Regina Elena Cancer Institute
    New trial
    2d
    MiGHT: Methods for Increasing Genetic Testing Uptake in Michigan (clinicaltrials.gov)
    P=N/A, N=831, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed
    Trial completion
    3d
    A prognostic model based on immune cells in tumor microenvironment to predict prognosis in endometrial cancer. (PubMed, BMC Cancer)
    This study identified two immune cell types-Stroma CD3+ and CD8+cells-significantly associated with the prognosis of EC and established a TIME-based prognostic model with robust predictive performance and accuracy.
    Journal
    |
    PD-L1 (Programmed death ligand 1) • CD163 (CD163 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD68 (CD68 Molecule)
    3d
    Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1/2, N=54, Recruiting, Icahn School of Medicine at Mount Sinai | Trial completion date: Sep 2026 --> Jul 2027
    Trial completion date • Platinum sensitive
    |
    cisplatin • Trodelvy (sacituzumab govitecan-hziy)